References
- 1. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996; 335(4):233.10.1056/NEJM199607253350403
- 2. Engels E, Biggar RJ, Hall H, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123:187-194.10.1002/ijc.23487
- 3. Rose LJ, Harris JE, Fishman AD, et al. Kaposi Sarcoma clinical presentation. http://emedicine.medscape.com/article/279734-clinical. [accessed 28.01.2015]
- 4 Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Int J Cancer. 2011;117:1089-1096.10.1002/cncr.25547
- 5. European Center for Diseases Control. HIV/AIDS surveillance in Europe 2008-2013. http://ecdc.europa.eu/en/ [accessed 28.01.2015]
- 6. Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7(9):1201-7.10.1200/JCO.1989.7.9.1201
- 7. Mitsuyasu RT. Clinical variants and staging of Kaposi’s sarcoma. Semin Oncol. Jun. 1987;14(2Suppl3):13-8
- 8. Stebbing J, Sanitt A, Nelson M, et al. A prognostic index for AIDS associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367:1495-502.10.1016/S0140-6736(06)68649-2
- 9. Jipa RE, Manea E., Benea S, et al. Characteristics of late presenters in Bucharest. J Int AIDS Soc. 2014;17(Suppl 3):19691.10.7448/IAS.17.4.19691422543125397441
- 10. Laney AS, Cannon MJ, Jaffe HW, et al. Human herpes virus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS. 2007;21:1541-1545.10.1097/QAD.0b013e3282202b7d17630548
- 11. Sofia Fernandes L. Human immunodeficiency virus and cancer. A population of HIV-infected patients at Hospital de Santa Maria and predictors of cancer. GERMS. 2012;2:60-74.10.11599/germs.2012.1014388286724432264
- 12. Lacombe JM, Boue F, Grabar S, et al. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. AIDS. 2013;27:635-43.10.1097/QAD.0b013e32835cba6c362327923196937
- 13. Agaba PA, Sule HM, Ojoh Ro, et al. Presentation and survival of patients with AIDS-related Kaposi’s sarcoma in Jos, Nigeria. Int J STD AIDS. 2009;20:410–41310.1258/ijsa.2008.00835319451327
- 14. Phipps W, Sewankambo F, Nguyen, et al. Gender differences in clinical presentation and outcomes of epidemic Kaposi Sarcoma in Uganda. PLoS ONE. 2010.5:e13936. doi:10.1371/journal.pone.0013936.10.1371/journal.pone.0013936
- 15. K. Chu., G. Mahlangeni, S. Swannet, et al. AIDS-associated Kaposi’s sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 2010;13:23.10.1186/1758-2652-13-23
- 16. Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32:409-14.10.1200/JCO.2013.51.6757
- 17. Martelotta F, Berretta M, Vacher E, et al. AIDS-Related Kaposi Sarcoma: State of the ART and therapeutic Strategies. Current HIV Research. 2009; 7:634-638.10.2174/157016209789973619
- 18. Krown SE, Northfelt DW, Osoba D, et al. Use of liposomal anthracyclines in Kaposi’s sarcoma. Semin Oncol. 2004;31:36-52.10.1053/j.seminoncol.2004.08.003
- 19. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8:167-176.10.1016/S1470-2045(07)70036-0
- 20. Kibria R, Siraj U, Barde C. Kaposi sarcoma of the stomach and duodenum in human immunodeficiency virus infection. Dig Endosc. 2010;22:241-2.10.1111/j.1443-1661.2010.00994.x20642618
- 21. Borie R, Cadranel J, Guihot A, Marcelin AG, et al. Pulmonary manifestations of human herpesvirus-8 during HIV infection. Eur Respir J. 2013;42:1105-18.10.1183/09031936.0015421223397298